NDMA objects to extending Reye syndrome warning to nonaspirin salicylates.
This article was originally published in The Rose Sheet
Executive Summary
NDMA OBJECTS TO EXTENDING REYE SYNDROME WARNING TO NONASPIRIN SALICYLATES based on a lack of scientific evidence and the fact that they are widely used and irreplaceable. In a Feb. 28 letter to FDA, the Nonprescription Drug Manufacturers Association asserted that it does "not believe that extension of the Reye syndrome warning to nonaspirin salicylates is warranted based on the lack of available evidence implicating nonaspirin salicylates used as excipients, or otherwise, as being associated with the development of Reye syndrome."